Sarah Cannon Research Institute And AstraZeneca Announce Personalized Medicine Partnership and Enhanced Strategic Clinical

  Sarah Cannon Research Institute And AstraZeneca Announce Personalized
  Medicine Partnership and Enhanced Strategic Clinical Development
  Collaboration

Business Wire

NASHVILLE, Tenn. & WILMINGTON, Del. -- July 1, 2013

Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced today a
collaboration in the field of personalized medicine to support development of
new AstraZeneca oncology compounds. Specifically, the parties will work
together on molecular profiling to classify tissue based upon genetic profiles
for the purpose of treating cancers and predicting response to therapy.

“Through our research, we know how vital and impactful individualized
treatment options are for patients battling this complex disease,” said Dee
Anna Smith, chief executive officer of SCRI. “By partnering with AstraZeneca,
we are expanding opportunities to accelerate drug development and deliver more
targeted therapies to patients who urgently need them.”

Under the agreement, SCRI will work with AstraZeneca to identify potential
patients for clinical trials and help explore biomarkers that predict response
to specific treatments. In addition, SCRI’s enhanced relationship with
AstraZeneca will provide clinical program development leadership, medical
expertise and oversight, and operational contract research organization (CRO)
trial management for early phase clinical development of multiple oncology
compounds.

“Building upon this unique collaboration with SCRI allows us to continue
honing our capabilities to deliver high quality research in a timely and
cost-effective manner,” said Vice President of Early Clinical Development for
AstraZeneca, Professor Andrew Hughes. “Through this cutting-edge program
design, we can rapidly and effectively implement clinical trials with greater
access to a network of cancer patients for enrollment.”

AstraZeneca is one of the initial participants in SCRI’s molecular profiling
program, which is part of Sarah Cannon’s broader personalized medicine
initiative across the United States and United Kingdom. SCRI and AstraZeneca
originally entered into an agreement to develop novel oncology compounds in
2010.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global strategic research
organization focusing on advancing therapies for patients. It is one of the
largest clinical research programs, conducting community-based clinical trials
in oncology and cardiology through affiliations with a network of more than
700 physicians in the United States and United Kingdom. Additionally, SCRI
offers management, regulatory and other research support services to drug
development sponsors and strategic investigator sites. For more information,
please visit us onsarahcannonresearch.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130701005400/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50662386&lang=en

Contact:

Sarah Cannon Research Institute
Anna Walker, 615-329-7216
Director, Brand Development & Communications
anna.walker@scresearch.net
or
AstraZeneca
Laura Woodin, 302-885-1087
Media Relations Lead-Global R&D
laura.woodin@astrazeneca.com
 
Press spacebar to pause and continue. Press esc to stop.